Novavax (NVAX) has had a long and bumpy road. Suffering badly after its key trial of an adult RSV vaccine went bust in 2016, the stock has tumbled downward, sitting below $1 a share for some time. A brief uptrend in July 2017 that saw the stock climb to $1.51 a share when a conference call was announced to discuss the future of the older adult RSV program. The market, unimpressed with a call that covered exactly what it promised to cover, pushed NVAX back down to around $1. Since then the stock has listed, slowly and sporadically climbing toward $1.15, almost exactly where it was the day before the July presentation.
While the July presentation and subsequent Q2 earnings report at the start of August have not done much to elevate NVAX’s share price, a presentation on Sep. 7 at the Citi 12th Annual Biotech Conference points the way forward and offers some fresh insights on the company’s strategy and future (the presentation slides were made available to non-attendees this week).
